BCDA - BioCardia, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

BCDA

BIOCARDIA, INC.

NASDAQ

$1.15

▼ DOWN 1.71% (-0.02)

KEY STATISTICS

Market Cap$17.12 M

52w High$2.29

52w Low$0.75

Dividend Yield—

Frequency—

P/E-1.26

Volume158.43K

Shares Out.14.88M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Peter A. Altman

COMPENSATION 2026

Salary$493,388

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$0

Total$493,388

ABOUT

SECTOR

Healthcare

WENT PUBLIC

November 13, 1996

METHOD OF GOING PUBLIC

Reverse Merger

FULL TIME EMPLOYEES

UPCOMING EARNINGS

DateNov 11, 2026

DayWednesday

Rev. Est.—

NOV

WED

SPLIT RECORD

DATE	TYPE	RATIO
2024-05-30	Reverse	1:15
2019-06-06	Reverse	1:9
2017-11-03	Reverse	1:12
2008-03-20	Reverse	1:10
2008-03-14	Reverse	1:10
2004-01-06	Forward	6:1
2001-08-23	Reverse	1:3

PRICE

$1.15 ▼ DOWN 1.71% (−$0.02)

OVERLAYS

About BioCardia, Inc.

https://www.biocardia.com ↗

BioCardia, Inc. is a clinical-stage regenerative medicine company developing cell-based therapies and delivery systems for cardiovascular and pulmonary diseases, including its lead CardiAMP Cell Therapy System for heart failure.

INDUSTRY

Biotechnology

A PRODUCT BIOCARDIA, INC. IS KNOWN FOR

Helix Transendocardial Delivery System

BioCardia's biotherapeutic delivery catheter enables minimally invasive, targeted delivery of biologics to the heart, serving as a key technology for their cell therapy platforms and currently under FDA review.